Loading company…
Sedivention develops minimally invasive medical devices for obesity treatment.
Founded in 2021 and based in Bayern, Germany, Sedivention develops medical devices for obesity treatment. Its cryo-ablation procedure targets gastric trunks of the vagus nerve and is designed to reduce hunger. The company is led by CEO Dr.-Ing. Andreas Brocker and was founded by André Burch and Dr.-Ing. Andreas Brocker. In April 2026, it raised EUR 2.9 million in seed funding led by BMP, with participation from superangels, Terumo Medical Corporation, Cambridge Capital Management, High-Tech Gruenderfonds, and other unspecified investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in